Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Change in Accured Expenses (2020 - 2025)

Vivos Therapeutics has reported Change in Accured Expenses over the past 6 years, most recently at $2.6 million for Q4 2025.

  • Quarterly Change in Accured Expenses rose 929.13% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, up 9376.92% year-over-year, with the annual reading at $3.6 million for FY2025, 9376.92% up from the prior year.
  • Change in Accured Expenses was $2.6 million for Q4 2025 at Vivos Therapeutics, up from $358000.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $2.6 million in Q4 2025 and troughed at -$538000.0 in Q3 2022.
  • The 5-year median for Change in Accured Expenses is $209500.0 (2021), against an average of $263100.0.
  • Year-over-year, Change in Accured Expenses surged 1360.23% in 2021 and then tumbled 1124.24% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $320000.0 in 2021, then soared by 146.25% to $788000.0 in 2022, then crashed by 58.38% to $328000.0 in 2023, then decreased by 22.56% to $254000.0 in 2024, then surged by 929.13% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Change in Accured Expenses are $2.6 million (Q4 2025), $358000.0 (Q3 2025), and $248000.0 (Q2 2025).